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Obesity and alcohol consumption synergistically promote steatohepatitis, and neutrophil infiltration is believed to be associated with steatosis. However, the underlying mechanisms remain obscure. Peroxisome proliferator-activated receptor gamma (PPARc) plays a complex role in lipid metabolism and inflammation; therefore, the purpose of this study was to dissect its role in regulating steatosis and neutrophil infiltration in a clinically relevant mouse steatohepatitis model of 3-month high-fat diet (HFD) feeding plus a binge of ethanol (HFD-plus-binge ethanol). Hepatocyte-specific Pparg disruption reduced liver steatosis but surprisingly increased hepatic neutrophil infiltration after HFD-plus-binge ethanol. Knockout or knockdown of the PPARc target gene, fat-specific protein 27, reduced steatosis without affecting neutrophil infiltration in this model. Moreover, hepatocyte-specific deletion of the Pparg gene, but not the fat-specific protein 27 gene, markedly up-regulated hepatic levels of the gene for chemokine (C-X-C motif) ligand 1 (Cxcl1, a chemokine for neutrophil infiltration) in HFD-plus-binge ethanol-fed mice. In vitro, deletion of the Pparg gene also highly augmented palmitic acid or tumor necrosis factor alpha induction of Cxcl1 in mouse hepatocytes. In contrast, activation of PPARc with a PPARc agonist attenuated Cxcl1 expression in hepatocytes. Palmitic acid also up-regulated interleukin-8 (a key chemokine for human neutrophil recruitment) expression in human hepatocytes, which was attenuated and enhanced by cotreatment with a PPARc agonist and antagonist, respectively. Finally, acute ethanol binge markedly attenuated HFDinduced hepatic PPARc activation, which contributed to the up-regulation of hepatic Cxcl1 expression post-HFD-plusbinge ethanol. Conclusion: Hepatic PPARc plays an opposing role in controlling steatosis and neutrophil infiltration, leading to dissociation between steatosis and inflammation; acute ethanol gavage attenuates hepatic PPARc activation and subsequently up-regulates hepatic CXCL1/interleukin-8 expression, thereby exacerbating hepatic neutrophil infiltration. (HEPATOLOGY 2017; 66:108-123 ). E xcess alcohol consumption and obesity renders increased risk for the development of steatohepatitis, cirrhosis, and hepatocellular carcinoma. (1) (2) (3) (4) The collaborative relationship between obesity and alcohol on steatohepatitis has been observed and documented in clinical studies (5) (6) (7) and in several animal models. (8) (9) (10) However, the mechanisms underlying the interaction of fat and alcohol on steatohepatitis have not been extensively investigated due to lack of appropriate animal models that reproduce the full spectrum of human steatohepatitis. (11) For example, very little overlap of gene expression patterns was found between liver tissues from various mouse models of nonalcoholic fatty liver disease (NAFLD) and patients with different stages of NAFLD. (12) Among these various models, only high-fat diet (HFD) feeding-associated hepatic gene expression change profiles were more similar to those in human fatty liver than other models. (12) HFD feeding for 3 months or longer resulted in severe steatosis and mild elevation of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) but limited inflammation with little neutrophil infiltration. Recently, we developed a mouse model of acute steatohepatitis (HFD-plus-binge ethanol model), in which administration of a single dose of ethanol after 3-month HFD feeding caused marked elevation of serum ALT and AST (reaching approximately 800 IU/L) and significant hepatic neutrophil infiltration. (13) This clinically relevant HFD-plusbinge ethanol model highlights the risk that even episodic binge drinking could cause significant hepatic neutrophil infiltration and acute steatohepatitis in obese/overweight individuals. However, how binge drinking/acute ethanol gavage promotes hepatic neutrophil infiltration in HFD-fed mice or in obese individuals is not fully understood. For example, does steatosis promote liver inflammation through neutrophil infiltration?
Peroxisome proliferation-activated receptors (PPARs) have three isoforms (PPARa, PPARb/d, and PPARc), which belong to the nuclear receptor superfamily of ligand-inducible transcription factors. (14) The identified PPARs differ from each other in terms of tissue distribution and ligand specificity, acting as important regulators of many genes involved in adipogenesis, glucose homeostasis, lipid metabolism, and inflammation. (15) Given the therapeutic potential for type 2 diabetes, PPARc attracted extensive clinical interest and therefore has been extensively studied (16) and tested in clinics for the treatment of NAFLD patients. (17) (18) (19) However, the results from the treatment of NAFLD by PPARc agonists have been mixed, (20) (21) (22) which is partly due to the complex cell-specific and tissue-specific PPARc functions. PPARc is highly expressed in adipose tissues but at very low levels in normal liver. (23) Expression of PPARc is markedly up-regulated in fatty livers in animal models (24, 25) and in patients with NAFLD. (26) Disruption of the Pparg gene in hepatocytes ameliorates steatosis, whereas overexpression promotes the development of fatty liver through the activation of various lipogenic genes, including fatspecific protein 27 (Fsp27), (27, 28) and the resultant lipogenesis. (23) (24) (25) 29) The Fsp27 gene has two forms, Fsp27a and Fsp27b. (30) Fsp27a is highly expressed in white adipose tissues, whereas Fsp27b is highly expressed in brown adipose tissues and fatty livers. (30) FSP27 is a lipid droplet protein that plays an important role in lipid droplet formation and promotes the development of fatty liver diseases. (27, 28, 31, 32) Although the steatogenic function of the PPARc-FSP27 axis is well documented, its role in hepatic neutrophil infiltration in steatohepatitis remains obscure.
Hepatic neutrophil infiltration is a hallmark of steatohepatitis and is believed to be associated with liver injury and disease progression by generating reactive oxygen species and producing proinflammatory mediators. (33) Our recent studies showed that blockade of several inflammatory mediators, such as chemokine (C-X-C motif) ligand 1 (CXCL1) and E-selectin, reduced hepatic neutrophil infiltration and ameliorated steatohepatitis in experimental animal model studies, confirming that neutrophil infiltration promoted hepatocyte injury. (13, 34) Although the mechanisms underlying neutrophil infiltration in steatohepatitis remain obscure, it is generally believed that steatosis positively correlated with inflammation and liver injury. In the current study, we revealed that hepatic loss of PPARc ameliorated liver steatosis but surprisingly aggravated hepatic neutrophil infiltration in mice treated with HFD-plus-binge ethanol. Mechanistically, we demonstrated that PPARc promoted steatosis through the up-regulation of FSP27 and attenuated hepatic neutrophil infiltration through the down-regulation of CXCL1/interleukin-8 (IL-8).
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Materials and Methods

MICE
Mice were housed in a temperature-controlled room with a 12-hour light/12-hour dark cycle. C57BL/6J mice, albumin-Cre mice, and Pparg fl/fl mice on a C57BL/6J background were purchased from the Jackson Laboratory (Bar Harbor, ME). Hepatocytespecific Pparg knockout (Pparg Hep-/-) mice were generated through several steps of crossing albumin-Cre mice and Pparg flox/flox mice in the National Institute on Alcohol Abuse and Alcoholism's animal facility. Hepatocyte-specific Fsp27 knockout mice (Fsp27
Hep-/-) on a C57BL6/N background were generated as reported in our previous study, and wild-type (WT) mice were used as controls. (27) All mice were cared for in accordance with the guidelines of the National Institutes of Health, and all animal experimental protocols were reviewed and approved by the National Institute on Alcohol Abuse and Alcoholism's animal care and use committee.
HFD-PLUS-BINGE ETHANOL MODEL
The HFD-plus-binge ethanol model has been described. (13) Briefly, male mice 8-12 weeks old were fed an HFD (60% kcal% fat; catalog no. D12492; Research Diet, New Brunswick, NJ) for 3 months. After 3 months of HFD feeding, mice received a single dose of ethanol (5 g/kg body weight as a 53.4% ethanol in water) by gavage at 7:00 AM and were killed 9 hours later. (13) Mice were not subjected to starvation before gavage. After gavage, mice were kept on a heating pad (378C), and the diet was removed.
MEASUREMENT OF SERUM AND LIVER FREE FATTY ACID LEVELS
Samples were prepared based on the manufacturer's instruction. Serum and liver free fatty acids (FFAs) were determined using a BioVision kit (no. K612-100; Milpitas, CA).
MEASUREMENT OF SERUM, SUPERNATANT, AND LIVER CXCL1 PROTEIN LEVELS
Samples were collected and prepared according to the manufacturer's instruction. Serum and liver CXCL1 levels and CXCL1 levels in supernatant from cultured hepatocytes were measured using an enzymelinked immunosorbent assay kit (no. SMKC00B; R&D Systems, Minneapolis, MN).
ADENOVIRUS Fsp27 SHORT HAIRPIN RNA AND ADENOVIRUS CONTROL SHORT HAIRPIN RNA
Generation and construction of adenovirus Fsp27 short hairpin RNA (shRNA; Ad-shFsp27) and adenovirus control shRNA (Ad-shRNA) were performed as described. (27) Briefly, mice fed the HFD for 3 months were injected with 10 9 pfu of Ad-shRNA or AdshFsp27 in a total volume of 200 lL phosphatebuffered saline by tail vein injection, then subjected to binge ethanol administration 6 days later.
STATISTICAL ANALYSIS
In this study, all data are shown as the mean 6 standard error of the mean (n 5 5-12 in each group). Group comparisons were performed using the unpaired t test or one-way analysis of variance, followed by Tukey's multiple comparisons as appropriate. P < 0.05 was considered statistically significant.
Results
HEPATIC Pparg DEFICIENCY IMPROVES HEPATIC STEATOSIS BUT DOES NOT AFFECT SERUM ALT AND AST LEVELS FOLLOWING HFD-PLUS-BINGE ETHANOL
Increased hepatic Pparg activation, a typical manifestation of fatty liver disease, promotes steatosis (24) ; and it is generally believed that reduced hepatic steatosis is correlated with decreased serum ALT and AST levels. (35) Thus, we postulated that Pparg Hep-/-mice had lower steatosis and liver injury than WT mice post-HFD-plus-binge ethanol. As expected, compared to WT mice, Pparg
Hep-/-mice had milder liver steatosis and lower hepatic triglyceride levels after HFD-plus-binge ethanol (Fig. 1A,B ), but surprisingly serum levels of ALT and AST were not reduced in Pparg
Hep-/-mice (Fig. 1C ). In addition, body weight gain and liver/body weight ratios were comparable between Pparg
Hep-/-mice and WT mice after HFDplus-binge ethanol (Supporting Fig. S1A ,B).
HEPATIC Pparg DEFICIENCY INCREASES Cxcl1 EXPRESSION AND NEUTROPHIL INFILTRATION FOLLOWING HFD-PLUS-BINGE ETHANOL
In our previous study, we demonstrated that acute inflammation played an important role in liver injury following HFD-plus-binge ethanol. (13) Because less steatosis but similar liver injury was found in Pparg
Hep-/-mice compared with WT mice, we postulated that there was more inflammation in Pparg
Hep-/-mice. To test our hypothesis, liver inflammation was examined by performing neutrophil marker myeloperoxidase (MPO) staining. The number of MPO 1 neutrophils was comparable in WT and Pparg
Hep-/-mice following HFD feeding without ethanol binge ( Fig. 2A,B) . However, despite milder steatosis, Pparg
Hep-/-mice had a greater degree of hepatic neutrophil infiltration than WT mice after HFD-plus-binge ethanol, which Total RNA was isolated and subjected to real-time PCR analysis of Ly6g (a marker of neutrophils) and other inflammatory genes. (E) Sera were collected to measure CXCL1 protein levels using an enzyme-linked immunosorbent assay kit. (F) Representative CXCL1 protein staining of liver tissue sections (black arrow indicates positive findings). *P < 0.05, **P < 0.01, ***P < 0.001.
was consistent with the finding that Ly6g (a marker for neutrophils) mRNA levels were higher in Pparg Hep-/-mice (Fig. 2C) . However, the number of Kupffer cells/ macrophages as detected by F4/80 staining in the liver was similar between Pparg
Hep-/-mice and WT mice (Supporting Fig. S2A) .
To understand the mechanisms by which Pparg
Hep-/-mice had greater hepatic neutrophil infiltration than WT mice after HFD-plus-binge ethanol, hepatic expression of several chemokines was examined. In HFD feeding alone groups without binge ethanol, hepatic expression of Cxcl1 mRNA was approximately 5-fold higher in Pparg
Hep-/-mice than WT controls, while hepatic expression of other inflammatory markers, including Cxcl2, Ly6g, IL-1b, IL-6, and P-Selectin, was comparable between WT and Pparg
Hep-/-mice (Fig. 2D ). Compared to the HFD feeding alone groups, HFD-plus-binge ethanol highly up-regulated hepatic expression of Cxcl1 in both WT and Pparg
Hep-/-mice, with much higher levels in Pparg
Hep-/-mice than in WT mice (Fig.  2D) . HFD-plus-binge ethanol also up-regulated hepatic expression of other inflammatory markers (such as Cxcl2, E-selectin, P-selectin) to a lesser extent, in both WT and Pparg
Hep-/-mice. Expression of these inflammatory mediators was not higher in Pparg
Hep-/-mice compared to WT mice. In addition, enzyme-linked immunosorbent assays confirmed that both hepatic and serum CXCL1 protein levels were much higher in Pparg
Hep-/-mice than WT mice following HFD-plusbinge ethanol ( Fig. 2E; Supporting Fig. S2B ). Moreover, immunohistochemical staining of CXCL1 also verified that there were more positive CXCL1-stained areas in Pparg
Hep-/-mice compared to WT controls following HFD-plus-binge ethanol (Fig. 2F) .
The above data indicated that acute binge ethanol induced much higher levels of hepatic expression of Ly6g (neutrophil marker) and Cxcl1 mRNAs in HFD-fed Pparg
Hep-/-mice than in HFD-fed WT mice. However, acute binge ethanol induced comparable levels of hepatic Ly6g and Cxcl1 mRNA expression in chow-fed WT and Pparg
Hep-/-mice (Supporting Fig. S2C ). The reason PPARc has no effect on liver inflammation in chow-fed mice after acute ethanol binge is probably that chow-fed mice have very low hepatic PPARc activation (lower nuclear PPARc) in contrast to highly activated hepatic PPARc in HFD-fed mice (24) (also see Results in the current study).
Fsp27 IS THE DOWNSTREAM SIGNAL OF Pparg-INDUCED STEATOSIS BUT DOES NOT AFFECT HEPATIC NEUTROPHIL INFILTRATION IN MICE WITH HFD-PLUS-BINGE ETHANOL
The above data suggest that PPARc promotes steatosis but inhibits neutrophil infiltration-induced inflammation. To understand the underlying mechanisms, we examined hepatic expression of Fsp27, a downstream target gene of PPARc, (28) 
(30) In our previous study, Fsp27 was reported to be highly up-regulated in mice in the chronic-plus-binge ethanol model, and up-regulation of Fsp27 contributed to alcohol-induced liver injury. (27) Here, we found that HFD-plus-binge ethanol induced much higher levels of hepatic Fsp27a and Fsp27b mRNA in mice than HFD feeding alone and that both Fsp27a and Fsp27b mRNA levels were markedly reduced in Pparg
Hep-/-mice compared to WT mice after HFD feeding or HFD-plus-binge ethanol (Fig. 3A) . In addition, mRNA encoding hepatic Cidea was reduced, but mRNA encoding hepatic Cideb was not reduced in Pparg
Hep-/-mice compared with WT mice (Fig. 3A) . In order to test the prosteatotic function of FSP27, Ad-shFsp27 was used to knock down Fsp27 gene expression. There were no changes in HFD consumption and body weight in mice 3 days or 6 days after injecting with Ad-shRNA and Ad-shFsp27 (Supporting Fig. S3A ). Both hepatic Fsp27a and Fsp27b mRNAs were lowered by Ad-shFsp27 injection, thus confirming that hepatic Fsp27 expression was reduced (Supporting Fig. S3B ).
In both the HFD feeding alone and the HFD-plusbinge ethanol groups, injection of Ad-shFsp27 reduced liver steatosis (Fig. 3B ) and ameliorated hepatic triglyceride levels (Supporting Fig. S3C ). Interestingly, compared to the shRNA control, injection of AdshFsp27 reduced serum ALT and AST levels in HFD-plus-binge ethanol groups but not in HFD feeding alone groups (Fig. 3C) .
Furthermore, genetic disruption of Fsp27 did not affect body weight (Supporting Fig. S3D ) but led to reduced steatosis in both HFD and HFD-plus-binge ethanol groups (Fig. 3D) . Both serum ALT and AST levels were markedly reduced in Fsp27
Hep-/-mice compared to WT mice in HFD-plus-binge ethanol groups, whereas only ALT levels were reduced in Fsp27 Hep-/-mice in HFD alone groups (Fig. 3E) . Thus, Fsp27 is responsible for the prosteatotic function of hepatic PPARc in this HFD-plus-binge ethanol model.
In order to investigate the anti-inflammatory function of Fsp27 in the HFD-plus-binge ethanol model, we tested neutrophil infiltration by performing MPO staining and real-time PCR analysis of Ly6g mRNA in mice with hepatic Fsp27 knockdown and Fsp27 disruption. Neither Fsp27 knockdown nor Fsp27 deletion Hep-/-and WT mice were set up for the HFDplus-binge ethanol model. Liver tissue samples were collected, and Cidea, Cideb, and Fsp27 mRNA expression was determined by real-time PCR. (B,C) Male C57BL/6N mice were fed the HFD for 3 months and administered Ad-shRNA (10 9 pfu) or Ad-shFsp27 (10 9 pfu) for the final 6 days. Ethanol (5 g/kg) was given by oral gavage 9 hours before killing. Liver tissues and sera were collected for measurement. Liver histology was analyzed, and serum ALT and AST levels were analyzed.
(D,E) Fsp27
Hep-/-mice and WT mice were set up for the HFD-plus-binge ethanol model. Liver histology is shown, and serum ALT and AST levels were analyzed. *P < 0.05, **P < 0.01, ***P < 0.001.
FIG. 4. Hepatic Fsp27 deletion does not affect neutrophil infiltration following HFD-plus-binge ethanol. (A,B)
Male C57BL/6N mice were fed the HFD for 3 months and administered Ad-shRNA (10 9 pfu) or Ad-shFsp27 (10 9 pfu) for the final 6 days. Ethanol (5 g/kg) was given by oral gavage 9 hours before killing. Liver tissues and sera were collected for measurement. Representative MPO staining is shown in ( altered the number of infiltrated neutrophils and hepatic expression of Ly6g in HFD feeding alone or in HFD-plus-binge ethanol groups, except for a mild increase in the number of infiltrated neutrophils following Fsp27 knockdown in HFD feeding alone (Fig.  4A-D) . Moreover, hepatic expression of Cxcl1 mRNA was not altered by hepatic Fsp27 knockdown or Fsp27 disruption (Fig. 4E) . The above data suggest that FSP27 does not play a role in inducing hepatic neutrophil infiltration and Cxcl1 mRNA expression in HFD-fed mice even when hepatic Fsp27 mRNA expression is highly elevated. Because FSP27 is expressed at very low levels in livers from chow-fed mice, (27) FSP27 very unlikely affects hepatic Cxcl1 mRNA expression and neutrophil infiltration in these mice.
HEPATIC Pparg DEFICIENCY REDUCES LIVER FIBROGENIC RESPONSE/FIBROSIS IN HFD-PLUS-BINGE ETHANOL
Liver steatosis and inflammation are associated with the development of fibrosis. (36) (37) (38) (39) Anti-inflammatory and antifibrogenic properties of PPARc in nonparenchymal liver cells have been reported. (40) Thus, we wondered whether hepatic PPARc also affected liver fibrogenic response/fibrosis in post-HFD-plus-binge ethanol. Compared to WT mice, Pparg
Hep-/-mice had fewer areas of sirius red staining following HFD feeding or HFD-plus-binge ethanol (Fig. 5A-C) . In addition, Tgfb, Col1a1, Col3a1, Col4a1, and Col12a1 mRNAs encoding fibrogenic markers were reduced in Pparg Hep-/-mice compared to WT mice post-HFDplus-binge ethanol.
As PPARc in hepatocytes oppositely regulates steatosis and inflammation, as demonstrated above, it remains a question whether steatosis dominantly modulates fibrosis instead of inflammation in the HFDplus-binge ethanol model. To answer this question, we further tested liver fibrosis by performing hepatic Fsp27 knockdown and Fsp27 knockout. Sirius red staining revealed that fewer fibrosis lesions were found in the Fsp27 knockdown and the Fsp27 knockout groups after both HFD feeding and HFD-plus-binge ethanol challenge (Supporting Fig. S4A,B) . Because knockdown/knockout of Fsp27 reduced steatosis but not inflammation, the data from Supporting Fig. S4 suggest that steatosis, not inflammation, plays a predominant role in promoting liver fibrosis in this HFDplus-binge ethanol model.
INTERACTION OF PPARc AND NUCLEAR FACTOR KAPPA B REGULATES CXCL1 EXPRESSION IN HEPATOCYTES
To understand the mechanisms by which activation of PPARc inhibits the up-regulation of Cxcl1 in the liver, we isolated primary hepatocytes and treated them with different regimens of palmitic acid (PA) and/or troglitazone (a PPARc agonist). Treatment with PA markedly up-regulated Cxcl1 mRNA expression in hepatocytes (Fig. 6A) . Interestingly, PA-mediated up-regulation of Cxcl1 mRNA was markedly enhanced in hepatocytes from Pparg
Hep-/-mice (12-fold induction in Pparg knockout hepatocytes versus a 2-fold change in WT hepatocytes). In addition, treatment with tumor necrosis factor alpha (TNF-a) up-regulated Cxcl1 mRNA expression in isolated hepatocytes, with much higher levels in Pparg knockout hepatocytes than WT hepatocytes (Fig. 6B) . In contrast, activation of PPARc by treatment with troglitazone attenuated TNF-a-mediated up-regulation of Cxcl1 mRNA and CXCL1 protein in hepatocytes (Fig. 6C) . Surprisingly, treatment with troglitazone did not affect PA-mediated up-regulation of Cxcl1 mRNA in hepatocytes (Supporting Fig. S5) . Moreover, we have demonstrated that nuclear factor kappa B (NFjB) activation is involved in the up-regulation of Cxcl1 mRNA in WT hepatocytes. (13) Here, we found that treatment with the NF-jB inhibitor Bay also markedly reduced PA-mediated induction of Cxcl1 mRNA in Pparg knockout hepatocytes (Fig. 6D) .
Finally, IL-8 is a functional homolog of mouse Cxcl1, and its expression in human hepatocytes is upregulated by PAs, (41) playing a critical role in promoting neutrophil infiltration in human steatohepatitis. Thus, we determined whether PPARc also regulates IL-8 expression in human hepatoma HepG2 cells. Treatment with PA induced IL8 mRNA in HepG2 cells. Cotreatment with the PPARc agonist troglitazone inhibited PA-mediated up-regulation of Il8 mRNA, whereas cotreatment with the PPARc antagonist GW9662 enhanced it (Fig. 6E) .
HFD FEEDING ACTIVATES HEPATIC PPARc, WHICH IS ATTENUATED BY A BINGE OF ETHANOL
Several murine models of obesity and diabetes developed fatty liver with enhanced levels of PPARc expression. (42) Studies have shown that the Pparg mRNA level was down-regulated in response to the combination of acute ethanol and lipopolysaccharide. (43) To further clarify the modulation of hepatic PPARc in response to HFD-plus-binge ethanol, we examined nuclear PPARc staining in this model. Very few Hep-/-mice and WT mice were isolated and stimulated with PA (0.3 mM) or TNF-a (10 ng/mL). Hepatocytes were collected, and Cxcl1 mRNA levels were determined by real-time quantitative PCR. (C) Primary hepatocytes from C57BL/6N mice were isolated and stimulated with troglitazone (a PPARc agonist) and TNF-a (10 ng/mL) for 12 hours; then, cells were harvested, and Cxcl1 mRNA levels were determined by real-time PCR.
(D) Primary hepatocytes from Pparg
Hep-/-mice and WT mice were isolated and stimulated by PA with pretreatment using different doses of Bay-7085 (an NF-jB inhibitor) for 30 minutes. Cxcl1 mRNA expression was determined by real-time PCR. (E) HepG2 cells were stimulated by PA with PPARc agonist (troglitazone) or antagonist (GW9662) pretreatment. Cells were collected after the treatment at different time points, and IL-8 mRNA levels were determined by real-time PCR. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: DMSO, dimethyl sulfoxide; Tro, troglitazone.
PPARc-positive nuclei of hepatocytes were detected in chow-fed and chow-plus-binge ethanol-fed mice (Fig.  7A) . However, a significant number of PPARc-stained nuclei of hepatocytes were found in mouse livers from HFD and HFD-plus-binge ethanol, with a lower number in the HFD-plus-binge ethanol group compared to the HFD feeding group. Western blot analyses confirmed that expression of nuclear PPARc protein (activated PPARc) in hepatocytes was increased by 12-fold in HFD-fed mice compared with chow-fed mice but significantly suppressed in HFD-plus-binge ethanol-fed mice compared to HFD alone-fed mice (Fig.  7B,C) . In addition, hepatic expression of total PPARc protein was higher in HFD-fed mice than in chow-fed mice, and acute ethanol binge markedly down-regulated hepatic expression of PPARc protein in HFD-fed mice FIG. 7 . Acute ethanol binge suppresses hepatic Pparg activation and expression in HFD-fed mice. C57BL/6J male mice were divided into four groups: two groups fed a chow diet and two groups fed the HFD for 3 months. On the last day of 3-month feeding, mice were given maltose or ethanol by oral gavage 9 hours before killing (Chow, Chow1binge, HFD, HFD1binge). Liver tissues were collected for further analysis. (A) Representative PPARc nuclear staining is shown (red arrows indicate positive staining of hepatocyte nucleus). (B,C) Total hepatic protein and hepatic nuclear protein were extracted and subjected to western blot analysis of total PPARc and nuclear PPARc protein. Representative blots are shown in (B). Quantification of total PPARc/ b-actin and nuclear PPARc/histone H3 is shown in (C). (D) Real-time PCR analysis of Pparg mRNA was performed. *P < 0.05, **P < 0.01, ***P < 0.001. (Fig. 7B,C) . Moreover, hepatic expression of Pparg mRNA was much higher in HFD-fed mice than in chow-fed mice, and such expression was markedly attenuated in mice following HFD-plus-binge ethanol (Fig. 7D ).
Discussion
Using a clinically relevant mouse steatohepatitis model induced by HFD-plus-binge ethanol, mechanistic insights into the role of steatosis and inflammation in liver disease were investigated, leading to several novel findings. First, hepatic PPARc promoted steatosis through Fsp27 up-regulation while attenuating neutrophil infiltration through CXCL1 suppression. Second, acute ethanol binge inhibits PPARc activation, which is partially responsible for acute ethanol-induced up-regulation of hepatic CXCL1. Third, acute ethanol gavage induces hepatic neutrophil infiltration in HFD-fed mice independent of steatosis. Finally, PPARc agonists also inhibit IL-8 expression in human hepatocytes. These findings were used to generate a working model depicting the interaction of fat and acute ethanol in promoting steatohepatitis (Fig. 8) .
The role of hepatic PPARc in the development of fatty liver has been well documented in several animal models of fatty liver induced by HFD feeding, (24) chronic ethanol feeding, (25) or genetic deletion of leptin. (23) Given that all of these models are associated with little liver inflammation (e.g., neutrophil infiltration), the effect of hepatic PPARc in liver inflammation has not been investigated and remains obscure. In the current study, we used a recently developed mouse model of HFD-plus-binge ethanol, which induces significant hepatic neutrophil infiltration, (13) to study the role of PPARc in modulating steatosis and neutrophil recruitment in the liver. The most striking finding was that although steatosis was reduced, hepatic neutrophil infiltration was markedly exacerbated in Pparg Hep-/-mice after HFD-plus-binge ethanol, suggesting that hepatic PPARc acts as an anti-inflammatory pathway through the inhibition of hepatic neutrophil infiltration. We previously demonstrated that hepatic CXCL1, a key chemokine in the promotion of neutrophil infiltration, was up-regulated by more than 30-fold after HFD-plus-binge ethanol and played an important role in hepatic neutrophil infiltration in this model. (13) Fascinatingly, in the current study, we found that hepatic and serum levels of CXCL1 protein were further elevated in Pparg
Hep-/-mice compared to those in WT mice (approximately 2,500 pg/mL in serum from Pparg
Hep-/-mice versus 1,200 pg/mL in WT) after HFD-plus-binge ethanol, indicating that hepatic PPARc played a critical role in inhibiting CXCL1 protein production in hepatocytes, thereby limiting hepatic neutrophil infiltration. The inhibitory effect of PPARc on Cxcl1 mRNA expression in PPARc also inhibits hepatic CXCL1 expression through the inhibition of NF-jB and subsequently reduces hepatic neutrophil infiltration. (B) Acute ethanol binge inhibits PPARc activation and subsequently diminishes the inhibitory effect of PPARc on the NF-jB/ CXCL1 axis, thus leading to CXCL1 up-regulation and massive hepatic neutrophil infiltration in HFD-fed mice. Acute ethanol also elevates FFA levels to further enhance the NF-jB/CXCL1 pathway.
hepatocytes was also confirmed in cultured primary hepatocytes as disruption of the Pparg gene in hepatocytes up-regulated fatty acid-induced or TNF-ainduced Cxcl1 mRNA, while activation of PPARc by treatment with the PPARc agonist troglitazone decreased TNF-a-induced Cxcl1 mRNA levels. Interestingly, activation of PPARc by troglitazone did not affect PA-mediated Cxcl1 mRNA expression in hepatocytes. The reason troglitazone treatment does not affect PA-mediated up-regulation of hepatic Cxcl1 mRNA is probably that PA itself is a strong ligand for PPARc activation (44) and thus may diminish the effect of PPARc agonist treatment.
Mechanistically, we also demonstrated that inhibition of NF-jB abolished PA-mediated up-regulation of Cxcl1 mRNA in Pparg
Hep-/-hepatocytes, suggesting that PPARc attenuates hepatic Cxcl1 mRNA levels through an NF-jB-dependent mechanism. Several studies have suggested that PPARc inhibited the expression of proinflammatory genes by interfering with NF-jB DNA binding. (45) (46) (47) (48) (49) This mechanism likely also explains the PPARc inhibition of Cxcl1 gene expression in hepatocytes through the inhibition of FFA activation of NF-jB. In addition, hepatic and serum FFA levels were comparable in Pparg Hep-/-mice compared to WT mice following HFD-plusbinge ethanol (Supporting Fig. S6A,B) . Taken together, these data suggest that up-regulated hepatic Cxcl1 mRNA expression in Pparg
Hep-/-mice is due to enhanced FFA signaling (through activation of NFjB) in hepatocytes and not to altered FFA levels compared to WT mice.
Liver fibrosis is always associated with steatosis and inflammation. Hepatic steatosis generally promotes liver fibrogenesis by producing reactive oxygen species and danger-associated molecule patterns, while inflammation plays a complex role in promoting or suppressing liver fibrogenesis. (37, 38) Interestingly, compared to WT mice, Pparg
Hep-/-mice had reduced liver steatosis and fibrosis, although these mice had enhanced liver inflammation post-HFD-plus-binge ethanol. These results suggest that hepatic PPARc promotes liver fibrosis through the stimulation of hepatic steatosis, while the anti-inflammatory effects of hepatic PPARc are less important for liver fibrosis in the HFD-plusbinge ethanol model.
Hepatic PPARc was up-regulated and activated in mice following HFD feeding (24, 25) or chronic ethanol feeding. (25) Here, we found that hepatic PPARc was also highly up-regulated and activated after HFD feeding but that, surprisingly, this up-regulation and activation were attenuated by an additional ethanol binge challenge. As a result, the attenuation of hepatic PPARc likely diminished the inhibitory effect of PPARc on hepatic neutrophil infiltration, resulting in highly elevated hepatic CXCL1 level and hepatic neutrophil infiltration observed in HFD-plus-binge ethanol-fed mice compared to HFD alone-fed mice. In addition, HFD feeding or acute ethanol gavage alone induced fat accumulation in the liver, but HFD-plusbinge ethanol did not further exacerbate steatosis compared to HFD feeding alone. (13) One possible explanation with regard to underlying mechanisms may be that, in addition to promote steatosis, acute ethanol binge reduced the steatogenic effect of PPARc through the inhibition of PPARc activation, resulting in comparable levels of steatosis in the HFD-plusbinge ethanol and HFD feeding groups. Another interesting observation was that acute ethanol binge down-regulated hepatic expression of PPARc protein and mRNA in HFD-fed mice, as demonstrated in the current study, but chronic ethanol feeding upregulated hepatic Pparg expression, as reported in another study. (25) However, the mechanisms by which hepatic PPARc is oppositely regulated by acute and chronic ethanol feeding remain unknown, and further studies are required to clarify.
Hepatic neutrophil infiltration, a hallmark of steatohepatitis, is generally believed to be associated with the degree of steatosis. (33) In the current study, we provided evidence suggesting that hepatic neutrophil infiltration is independent of steatosis in the HFD-plusbinge ethanol model. First, Pparg
Hep-/-mice had significantly reduced steatosis but increased hepatic neutrophil infiltration compared to WT mice post-HFDplus-binge ethanol. Second, inhibition of the PPARc downstream target gene Fsp27 also markedly improved steatosis but did not affect hepatic neutrophil infiltration and hepatic Cxcl1 mRNA expression in mice fed HFD-plus-binge ethanol.
Another important finding from the current study is that activation of PPARc not only inhibits PAmediated induction of CXCL1 in mouse hepatocytes but also suppresses PA stimulation of IL-8, a functional homolog of mouse CXCL1, in human hepatocytes. PA induction of IL-8 in human hepatocytes likely plays an important role in promoting neutrophil infiltration and disease progression in human nonalcoholic steatohepatitis (NASH). (41) Thus, treatment with PPARc agonists may be beneficial for human NASH through the inhibition of IL-8 production in hepatocytes.
CLINICAL IMPLICATIONS OF THIS STUDY
The complex effects of PPARc on hepatic steatosis, fibrosis, and neutrophil infiltration compromise the potential use of PPARc as a therapeutic target for the treatment of NASH. (19) The PPARc agonist pioglitazone, a prescription drug for type 2 diabetes, should be cautiously used for the treatment of NASH because activation of hepatic PPARc, while beneficial for the inhibition of neutrophil infiltration, could exacerbate steatosis and fibrosis. Furthermore, the PPARc-NFjB-CXCL1/IL-8 axis identified in the current study yields new insights into the development of potential treatment of neutrophil-mediated steatohepatitis, reflecting the synergistic effect of obesity and alcohol consumption in hepatic neutrophil infiltration.
